#USA #San Francisco #Breast Cancer #Cancer Prevention #Human Longevity

Human Longevity Expands Its Cancer Prevention Pledge

In a significant development aimed at enhancing breast cancer management, Human Longevity, Inc. (HLI) has announced an expansion of its Cancer Prevention Pledge program. This expansion provides up to $1 million in treatment and clinical support specifically for individuals diagnosed with stage IV breast cancer. The initiative is designed to bolster early detection efforts and improve health outcomes for affected individuals.

A Commitment to Early Detection

HLI’s approach is centered on a commitment to proactive healthcare. Dr. Wei-Wu He, CEO and Chairman of Human Longevity, expressed confidence in HLI's integrated detection strategies. He stated, "We are so confident in our integrated detection approach that we believe no member under our ongoing care should reach stage IV breast cancer without prior detection." This statement underscores HLI’s ambition to minimize the number of advanced-stage cancer cases among their members.

To achieve this goal, HLI utilizes a comprehensive strategy for personalized risk assessment and monitoring. This includes:

• - Whole Genome Sequencing: A detailed analysis of the BRCA1, BRCA2 genes and other inherited cancer risk factors.
• - Enhanced Breast Screening: The use of risk-based mammography and dedicated breast MRI, supplemented with liquid biopsies when necessary, to ensure comprehensive evaluation.
• - AI-Enabled Analysis: The integration of genetic, imaging, and clinical data allows for ongoing physician-guided care and timely follow-up.

Support for Advanced Cancer Treatment

As part of the expanded pledge, HLI is also dedicated to providing access to emerging treatment options for eligible members. According to Dr. He, innovative therapies such as investigational mRNA vaccines and tumor-infiltrating lymphocyte (TIL) therapies might be utilized, contingent on clinical eligibility and regulatory clearance. This focus on precision medicine aims to offer personalized treatment avenues that align with the unique needs of each patient.

Understanding the Eligibility Requirements

To qualify for the benefits of the $1 million Cancer Prevention Pledge, members are required to adhere to HLI’s ongoing care protocols. This includes maintaining continuous enrollment in either HLI's Executive Health Program or an eligible Longevity Program, completing recommended screenings, and following the Cancer Screening Commitment Agreement. Support for eligible individuals diagnosed with stage IV breast cancer may encompass:

• - Coverage for qualifying treatment costs
• - Coordination of care among specialists
• - Personalized treatment planning that aligns with their unique health profiles

The terms of eligibility and covered services are dictated by the agreements and specific program guidelines, ensuring that the assistance provided is tailored to address the individual circumstances of each participant.

About Human Longevity

Human Longevity, Inc. stands at the forefront of precision health and longevity. By merging genomics, artificial intelligence, advanced imaging, and comprehensive diagnostics, the company aims to extend the healthspan of individuals through personalized evaluations and ongoing health management. The recent expansion of the Cancer Prevention Pledge signifies HLI's commitment to fostering advancements in cancer care and supporting patients facing formidable health challenges.

For additional information about HLI and their innovative health programs, please visit Human Longevity's website.